# Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population

> **NCT01337336** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** fluticasone propionate/salmeterol xinafoate
- **DRUG:** Anticholinergics

## Key facts

- **NCT ID:** NCT01337336
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2010-11
- **Final completion:** 2011-03
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01337336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01337336, "Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01337336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*